U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc ...
- U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc for $1.05 billion in cash, gaining access to the privately held company’s lead kidney cancer drug candidate.
Merck’s blockbuster immunotherapy Keytruda was approved last month in the United States for treating renal cell cancer. In an older mid-stage trial testing patients whose cancer had spread even after treatment with at least one therapy, 24% of patients treated with Peloton’s drug showed an at least 30% shrinkage of targeted lesions.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Merck to buy cancer drug developer Peloton for $1.05 billion in cashMerck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 b...
Leer más »
Merck's Keytruda fails as monotherapy in breast cancer studyMerck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to mee...
Leer más »
Supreme Court gives Merck another shot to avoid Fosamax lawsuitsThe U.S. Supreme Court on Monday gave Merck & Co a new opportunity to avoid laws...
Leer más »
Pharma giant Merck just struck a $1 billion deal for a drugmaker working on a new treatment for kidney cancerMerck is acquiring Peloton Therapeutics for $1 billion in cash to gain access to a treatment the company is developing for kidney cancer.
Leer más »
U.S. Supreme Court tosses ruling against Merck on Fosamax osteoporosis drugSupreme Court rules for Merck on claims it failed to warn about fracture risk from osteoporosis drug Fosamax
Leer más »
Supreme Court blocks bid to sue Merck over Fosamax bone fracturesSupreme Court unanimously blocks, for now, a class-action lawsuit against pharmaceutical giant Merck over 'atypical femoral fractures' caused by osteoporosis drug Fosamax.
Leer más »
Merck to buy cancer drug developer Peloton for $1.05 billion in cashMerck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 b...
Leer más »
Pharma giant Merck just struck a $1 billion deal for a drugmaker working on a new treatment for kidney cancerMerck is acquiring Peloton Therapeutics for $1 billion in cash to gain access to a treatment the company is developing for kidney cancer.
Leer más »
Merck's Keytruda fails as monotherapy in breast cancer studyMerck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to mee...
Leer más »
Novartis' cancer treatment Kymriah gets Japan nod at cost of $305,800A Japanese government panel approved Novartis' cancer treatment Kymriah at ...
Leer más »
‘This terrible disease’: Ovarian cancer is deadly, but new tests, treatments start to emergeCompared with other cancer success stories, the disease historically has had a shortage of good news. Until recently, it hasn’t benefited from new treatments for decades.
Leer más »